» Articles » PMID: 35543272

Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019

Abstract

Background: Laboratory screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key mitigation measure to avoid the spread of infection among recruits starting basic combat training in a congregate setting. Because viral nucleic acid can be detected persistently after recovery, we evaluated other laboratory markers to distinguish recruits who could proceed with training from those who were infected.

Methods: Recruits isolated for coronavirus disease 2019 (COVID-19) were serially tested for SARS-CoV-2 subgenomic ribonucleic acid (sgRNA), and viral load (VL) by reverse-transcriptase polymerase chain reaction (RT-PCR), and for anti- SARS-CoV-2. Cluster and quadratic discriminant analyses of results were performed.

Results: Among 229 recruits isolated for COVID-19, those with a RT-PCR cycle threshold >30.49 (sensitivity 95%, specificity 96%) or having sgRNA log10 RNA copies/mL <3.09 (sensitivity and specificity 96%) at entry into isolation were likely SARS-CoV-2 uninfected. Viral load >4.58 log10 RNA copies/mL or anti-SARS-CoV-2 signal-to-cutoff ratio <1.38 (VL: sensitivity and specificity 93%; anti-SARS-CoV-2: sensitivity 83%, specificity 79%) had comparatively lower sensitivity and specificity when used alone for discrimination of infected from uninfected.

Conclusions: Orthogonal laboratory assays used in combination with RT-PCR may have utility in determining SARS-CoV-2 infection status for decisions regarding isolation.

Citing Articles

Intranasal inoculation of female BALB/c mice with replication-deficient human adenovirus type 5 expressing SARS-CoV-2 nucleocapsid protein aggravates lung pathology upon re-encountering the antigen.

Cao J, Gu H, Zhang X, Yun H, Li J, Si C Virus Res. 2023; 335:199201.

PMID: 37595663 PMC: 10470087. DOI: 10.1016/j.virusres.2023.199201.


Evaluating SARS-CoV-2 Saliva and Dried Blood Spot Surveillance Strategies in a Congregate Population.

Andronescu L, Richard S, Laing E, Pisanic N, Coggins S, Rivera M Emerg Infect Dis. 2023; 29(9):1925-1928.

PMID: 37579513 PMC: 10461675. DOI: 10.3201/eid2909.230417.


Analytical validation of quantitative SARS-CoV-2 subgenomic and viral load laboratory developed tests conducted on the Panther Fusion® (Hologic) with preliminary application to clinical samples.

Lakhal-Naouar I, Hack H, Moradel E, Jarra A, Grove H, Ismael R PLoS One. 2023; 18(6):e0287576.

PMID: 37384714 PMC: 10309597. DOI: 10.1371/journal.pone.0287576.


Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants.

Dimcheff D, Blair C, Zhu Y, Chappell J, Gaglani M, McNeal T J Infect Dis. 2023; 228(3):235-244.

PMID: 36883903 PMC: 10420395. DOI: 10.1093/infdis/jiad061.

References
1.
Wilson E, Donovan C, Campbell M, Chai T, Pittman K, Sena A . Multiple COVID-19 Clusters on a University Campus - North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(39):1416-1418. PMC: 7537562. DOI: 10.15585/mmwr.mm6939e3. View

2.
Verma R, Kim E, Martinez-Colon G, Jagannathan P, Rustagi A, Parsonnet J . SARS-CoV-2 Subgenomic RNA Kinetics in Longitudinal Clinical Samples. Open Forum Infect Dis. 2021; 8(7):ofab310. PMC: 8291522. DOI: 10.1093/ofid/ofab310. View

3.
van Kampen J, van de Vijver D, Fraaij P, Haagmans B, Lamers M, Okba N . Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021; 12(1):267. PMC: 7801729. DOI: 10.1038/s41467-020-20568-4. View

4.
Dinnes J, Deeks J, Berhane S, Taylor M, Adriano A, Davenport C . Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021; 3:CD013705. PMC: 8078597. DOI: 10.1002/14651858.CD013705.pub2. View

5.
Santos Bravo M, Nicolas D, Berengua C, Fernandez M, Hurtado J, Tortajada M . Severe Acute Respiratory Syndrome Coronavirus 2 Normalized Viral Loads and Subgenomic RNA Detection as Tools for Improving Clinical Decision Making and Work Reincorporation. J Infect Dis. 2021; 224(8):1325-1332. PMC: 8436374. DOI: 10.1093/infdis/jiab394. View